Amarin Corporation plc (ADR) (AMRN) was Initiated by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $6. Cantor Fitzgerald advised their investors in a research report released on Oct 5, 2016.
On the company’s financial health, Amarin Corporation plc (ADR) reported $-0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.13. The company had revenue of $32.81 million for the quarter, compared to analysts expectations of $29.30 million. The company’s revenue was up 85.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.15 EPS.
Amarin Corporation plc (ADR) (AMRN) witnessed a volatile trading activity on Tuesday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $3.19 and reached the intraday high at $3.24. The bulls started the profit booking and pushed the shares to intraday low of $3.16. The trading session was marked by a volume range of 15,59,617 shares exchanging hands. The 52-week high of the shares is $3.46 and the 52-week low is $1.24. The market cap of the company stands at $593 M and there are 18,52,85,760 shares in public circulation.
In a different news, on Feb 3, 2016, John F Thero (CEO) purchased 25,000 shares at $1.37 per share price.
Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarin’s lead product Vascepa (icosapent ethyl) capsules are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers as well as regional wholesalers and specialty pharmacy providers who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.